Glaxo to co-develop Futura’s OTC impotence gel
If successful, the drug, currently known as MED2002, would be the world’s first non-prescription pharmaceutical treatment for men with erectile dysfunction (ED). Under the terms of the agreement,
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
The product (lamivudine-zidovudine-nevirapine tablet) contains the active ingredients in GlaxoSmithKline’s Epivir (lamivudine) and Retrovir (zidovudine), and Boehringer Ingelheim’s Viramune (nevirapine), all widely used antiretroviral drugs. The agency’s tentative